study (data underestimation), the possible variability among professionals in the different centers, the coordination of levels (health care continuum), and the lack of prescribed dose adjustment (Tandon et al 2006). Nevertheless, such reformed centers present a very similar intervention orga- nizational and protocol model – thus ensuring a common and homogeneous health care level. In future, new studies will be needed to conﬁrm the consistency of the results obtained, and to evaluate strategies designed to reduce the cardiovascular risk factors. Likewise, it is important to continue advancing in treatment compliance and the achievement of objectives, in order to ensure more cost- effective interventions (Tandon et al 2006). In conclusion, obesity is an important cardiovascular risk factor signiﬁcantly associated with the use of APDs in the presence of hypertension, diabetes and dyslipid- emia, and with patient age and sex as nonmodiﬁable fac- tors, leading to an increased consumption of health care resources. In our sample, no differences were recorded between the uses of conventional or atypical APDs, though further research under normal clinical practice conditions will be needed to reinforce the consistency of these results. Disclosure There are no conﬂicts of interest to report. References [ADA] American Diabetes Association, American Psychiatric Associa- tion, American Association of Clinical Endocrinologists, et al. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27:596–601. Aranceta-Bartrina J, Serra-Majem Ll, Foz-Sala M, et al. 2005. Prevalencia de obesidad en España. Med Clin (Barc), 125:460–6. Babidge NC, Buhrich N, Butler T. 2001. Mortality among homeless people with schizophrenia in Sydney, Australia: a 10-year follow-up. Acta Psychiatr Scand, 103:105–10. Barnett M, Argo T, Alexander B, et al. 2006. A regional comparison of developing diabetes among Veterans Affairs patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors. Ann Clin Psychiatry, 18:1–7. Dinca O, Paul M, Spencer NJ. 2005. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. J Psychopharmacol, 19:521–32. Fenton WS, Chavez MR. 2006. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry, 163:1697–1704. Flores-Meneses L, Sanmarti-Sala A. 2005. Atypical antipsychotics: new aetiology in type 2 diabetes mellitus. Med Clin (Barc), 124:341–3. Garcia-Cardona F, Molins-Perez G, Farre-Pradell J, et al. 1995. Cost accountability in primary care: list of services. Aten Primaria, 16:141–5. Gómez P, Fernández de la Puebla RA, Castro P, et al. 2005. Effect of the Mediterranean diet on fasting concentrations of activated factor VII in healthy persons. Rev Esp Cardiol, 58:285–9. Neuropsychiatric Disease and Treatment 2008:4(1) Obesity and the use of antipsychotic drugs Guallar-Castillón P, Banegas-Banegas JR, García-Yébenes MJ. 2002. Asociación de la enfermedad cardiovascular con el sobrepeso y la obesidad en España. Med Clin (Barc), 118:616–18. Gutiérrez-Fisac JL, Regidor E, Rodríguez-Artalejo F. 2005. Prevalencia de obesidad en la población adulta española: 14 años de incremento continuado. Med Clin (Barc), 124:196–7. Hagg S, Lindblom Y, Mjorndal T, et al. 2006. High prevelence of the meta- bolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol, 21:93–8. Haupt DW. 2006. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol, 16(Suppl)3:S149–55. Hiroeh U, Appleby L, Mortensen PB, et al. 2001. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population- based study. Lancet, 358:2110–12. Jin H, Meyer JM, Jeste DV. 2004. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res, 71:195–212. Kane JM, Barret EJ, Casey DE, et al. 2004. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry, 65:1447–55. Katerndahl DA. 1995. Problemas conductuales y psiquiátricos. In: Taylor RB ed. Medicina de familia, principios y práctica. 5ª ed. New York: Springer, pp. 289–331. Kokkinos P, Panagiotakos DB, Polychronopoulos E. 2005. Dietary inﬂuences on blood pressure: the effect of the Mediterranean diet on the prevalence of hypertension. J Clin Hypertens (Greenwich), 7:165–70. Lamberts H, Wood M, Hofmans-Okkes IM. 1993. The International Classiﬁcation of Primary Care in the European Community. With a multi-language layer. Oxford: Oxford University Press. Mackin P, Watkinson HM, Young AH. 2005. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia, 48:215–21. McIntyre RS, McCann SM, Kennedy SH. 2001. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry, 46:273–81. Morgan MG, Scully PJ, Youssef HA, et al. 2003. Prospective analysis of premature mortality in schizophrenia in relation to health ser- vice engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res, 117:127–35. [NCEP] National Cholesterol Education Program – Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002.Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III ﬁnal report. Circulation, 106:3143–421. Orden de la Generalitat de Catalunya de 22 de diciembre de 1995. Diari Oﬁcial de la Generalitat de Catalunya. 2148:9689–90. Pujol-Domenech J, de-Azpiazu-Artigas P. 2006. Antipsychotics in the elderly: typical or atypical. Med Clin (Barc), 126:415–17. Ryan MC, Thakore JH. 2002. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci, 71:239–57. Schneider LS, Dagerman K, Insel PS. 2006. Efﬁcacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry, 14:191–210. Tandon R, Nasrallah HA. 2006. Subjecting meta-analyses to closer scrutiny: Little support for differential efﬁcacy among second-generation antipsy- chotics at equivalent doses. Arch Gen Psychiatry, 63:935–7. Thompson SG, Barber JA. 2000. How should cost data in pragmatic randomised trials be analysed? BMJ, 320:1197–200. Ustun TB. 1999. The global burden of mental disorders. Am J Public Health, 89:1315–18. Vázquez JL, García J, Simón JA, et al. 1997. Mental health in primary care. An epidemiological study of morbidity and use of health resources. Br J Psychiatry, 170:529–35. Vedia C, Bonet S, Forcada C, et al. 2005. Estudio de utilización de psicofármacos en atención primaria. Aten Primaria, 36:239–47. 225